Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Record of Telephone Conversation, April 30, 2012 - Q-Pan

Submission Type: BLA

Submission ID: 125419/0

Office: OVRR


Product:
Influenza A (H5N1) Virus Monovalent Vaccine

Applicant:
GlaxoSmithKline Biologicals

Telecon Date/Time: 30-Apr-2012 11:48 AM Initiated by FDA? Yes

Telephone Number: 610-787-3435

Communication Categorie(s):
1. Information Request

Author: CARMEN COLLAZO-CUSTODIO

Telecon Summary:
356h form and SRID testing

FDA Participants: CARMEN COLLAZO-CUSTODIO

Non-FDA Participants: Michael Schwartz

Telecon Body:
The following was communicated to GSK via e-mail correspondence:


From: Collazo, Carmen
Sent: Monday, April 30, 2012 11:48 AM
To: 'Michael Schwartz'
Cc: 'Kati Abraham'; Wally, Jeremy; Prutzman, Kirk C; Collazo, Carmen
Subject: Information Request STN 124419 Q-Pan H5N1

Dear Michael,

We have the following request for information:

  1. Please submit a revised 356h form reflecting the correct license information.
  2. CBER received the monovalent -(b)(4) but need the following information:
    1. Please indicate the reagents used in the SRID testing.
    2. Please provide the SRID results you obtained with the monovalent lots: -----------------(b)(4)-----------------------------------.

Thank you!!

Carmen M. Collazo-Custodio, Ph.D.
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research
U.S. Food and Drug Administration

Office location:
1451 Rockville Pike Rm. 2236
Rockville, MD 20852
Tel. 301-796-2640
Fax: 301-827-3532
E-mail address: carmen.collazo@fda.hhs.gov

Mailing address:
Center for Biologics Evaluation and Research
Document Control Center HFM-481
1401 Rockville Pike
Rockville, MD 20852-1448

Page Last Updated: 01/22/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.